Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China flag China · Delayed Price · Currency is CNY
13.57
+0.04 (0.30%)
Feb 27, 2026, 3:04 PM CST

SHE:002727 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Jan '23 Jan '22 Dec '20
Operating Revenue
16,87317,46216,87717,12414,27512,401
Other Revenue
538.72538.72503.73307.42312.21255.01
17,41218,00017,38017,43214,58712,656
Revenue Growth (YoY)
-4.10%3.57%-0.29%19.50%15.26%20.78%
Cost of Revenue
11,93012,42811,79811,4869,3208,211
Gross Profit
5,4825,5735,5825,9465,2674,446
Selling, General & Admin
5,1315,1664,6634,5124,0873,541
Research & Development
10.759.7110.28.745.390.84
Other Operating Expenses
-10.667.6732.6217.17-13.930.55
Operating Expenses
5,1475,1904,7394,6284,0823,546
Operating Income
334.45383.26843.931,3181,185899.78
Interest Expense
-135.91-146.04-135.34-93.72-136.22-24.54
Interest & Investment Income
24.3147.0486.487.4953.5258.39
Currency Exchange Gain (Loss)
---0.23-0.09-0.34
Other Non Operating Income (Expenses)
17.19-7.75-93.761.48-4.53-2.42
EBT Excluding Unusual Items
240.05276.51701.321,2331,098930.86
Impairment of Goodwill
-26.77-26.77-11.65-12.29-10.97-13.19
Gain (Loss) on Sale of Investments
1.99-3.43-8.36-5.72-5.77-
Gain (Loss) on Sale of Assets
14.73.181.12-13.83-13.41-0.02
Asset Writedown
11.99-2.17-2.93-13.85-2.71-2.45
Other Unusual Items
-40-4023.0747.4831.2941.7
Pretax Income
201.95207.31702.561,2351,097956.89
Income Tax Expense
118.3797.02142.15222179.32167.73
Earnings From Continuing Operations
83.57110.29560.411,013917.21789.17
Minority Interest in Earnings
6.653.85-10.97-2.984.380.79
Net Income
90.23114.14549.441,010921.58789.96
Net Income to Common
90.23114.14549.441,010921.58789.96
Net Income Growth
-42.17%-79.23%-45.60%9.59%16.66%30.81%
Shares Outstanding (Basic)
584592597593590572
Shares Outstanding (Diluted)
584592597595592573
Shares Change (YoY)
-2.25%-0.76%0.27%0.50%3.32%0.88%
EPS (Basic)
0.150.190.921.701.561.38
EPS (Diluted)
0.150.190.921.701.561.38
EPS Growth
-40.84%-79.07%-45.75%9.05%12.91%29.67%
Free Cash Flow
1,6331,4661,8622,1481,400753.18
Free Cash Flow Per Share
2.792.483.123.612.361.31
Dividend Per Share
0.5000.3000.4000.4000.3000.300
Dividend Growth
25.00%-25.00%-33.33%--
Gross Margin
31.48%30.96%32.12%34.11%36.11%35.13%
Operating Margin
1.92%2.13%4.86%7.56%8.13%7.11%
Profit Margin
0.52%0.63%3.16%5.79%6.32%6.24%
Free Cash Flow Margin
9.38%8.14%10.71%12.32%9.60%5.95%
EBITDA
432.6492.77968.591,4321,283979.56
EBITDA Margin
2.48%2.74%5.57%8.22%8.80%7.74%
D&A For EBITDA
98.15109.51124.66114.4698.0879.78
EBIT
334.45383.26843.931,3181,185899.78
EBIT Margin
1.92%2.13%4.86%7.56%8.13%7.11%
Effective Tax Rate
58.62%46.80%20.23%17.98%16.35%17.53%
Revenue as Reported
17,41218,00017,38017,43214,58712,656
Advertising Expenses
-62.949.5549.2842.1623.93
Source: S&P Global Market Intelligence. Standard template. Financial Sources.